Destiny Pharma plc: Second positive Phase 1 trial data from XF-73

Primary objective achieved by both XF-73 concentrations

January 28, 2019
Destiny Pharma plc

Brighton, United Kingdom - 28 January 2019 - Destiny Pharma (AIM: DEST), a clinical stage biotechnology company focused

on the development of novel antimicrobial drugs, which address the global problem of antimicrobial resistance (AMR), today

announces positive data and the non-irritant classification for its XF-73 nasal gel from the second Phase 1 safety clinical study

examining the drug's potential to cause irritation when administered topically.

Full PR available here: